88. N. Davidsohn et al., Accurate predictions of genetic circuit
behavior from part characterization and modular
composition. ACS Synth. Biol. 4, 673–681 (2015).
doi: 10.1021/sb500263b; pmid: 25369267
89. J. Y. Dong, P. D. Fan, R. A. Frizzell, Quantitative analysis of
the packaging capacity of recombinant adeno-associated
virus. Hum. Gene Ther. 7, 2101–2112 (1996). doi: 10.1089/
hum.1996.7.17-2101; pmid: 8934224
90. A. L. Epstein, Progress and prospects: Biological properties
and technological advances of herpes simplex virus type
1-based amplicon vectors. Gene Ther. 16, 709–715 (2009).
doi: 10.1038/gt.2009.42; pmid: 19369969
91. H. Yin et al., Non-viral vectors for gene-based therapy.
Nat. Rev. Genet. 15, 541–555 (2014). doi: 10.1038/nrg3763;
92. M. A. Maier et al., Biodegradable lipids enabling rapidly
eliminated lipid nanoparticles for systemic delivery of RNAi
therapeutics. Mol. Ther. 21, 1570–1578 (2013). doi: 10.1038/
mt.2013.124; pmid: 23799535
93. J. Hoggatt, Gene therapy for “Bubble Boy” disease. Cell 166,
263 (2016). doi: 10.1016/j.cell.2016.06.049; pmid: 27419862
94. C. Kloks et al., A fit-for-purpose strategy for the risk-based
immunogenicity testing of biotherapeutics: A European
industry perspective. J. Immunol. Methods 417, 1–9 (2015).
doi: 10.1016/j.jim.2015.01.003; pmid: 25602137
95. A. C. Nathwani et al., Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med.
365, 2357–2365 (2011). doi: 10.1056/NEJMoa1108046;
96. A. C. Nathwani et al., Long-term safety and efficacy of
factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371,
1994–2004 (2014). doi: 10.1056/NEJMoa1407309;
97. R. A. Maldonado et al., Polymeric synthetic nanoparticles for
the induction of antigen-specific immunological tolerance.
Proc. Natl. Acad. Sci. U.S.A. 112, E156–E165 (2015).
doi: 10.1073/pnas.1408686111; pmid: 25548186
98. T. K. Kishimoto et al., Improving the efficacy and safety of biologic
drugs with tolerogenic nanoparticles. Nat. Nanotechnol. 11,
890–899 (2016). doi: 10.1038/nnano.2016.135; pmid: 27479756
99. E. Sands, paper presented at the Annual European Congress
of Rheumatology, Madrid, Spain, 15 June 2017.
100. R. M. Blaese et al., T lymphocyte-directed gene therapy for
ADA– SCID: Initial trial results after 4 years. Science 270,
475–480 (1995). doi: 10.1126/science.270.5235.475;
101. A. Aiuti, M. G. Roncarolo, L. Naldini, Gene therapy for
ADA– SCID, the first marketing approval of an ex vivo gene
therapy in Europe: Paving the road for the next generation of
advanced therapy medicinal products. EMBO Mol. Med. 9,
737–740 (2017). doi: 10.15252/emmm.201707573;
102. E. Dolgin, Epic $12 billion deal and FDA’s approval raise
CAR-T to new heights. Nat. Biotechnol. 35, 891–892 (2017).
doi: 10.1038/nbt1017-891; pmid: 29019995
We thank S. Kiani for critical discussions. This work was supported
by research grants to R. W. from the Defense Advanced Research
Projects Agency (DARPA-BAA-11-23), the NIH (CA207029), and
the NSF (CNS-1446607), and by the Ragon Institute of Massachusetts
General Hospital (MGH), Massachusetts Institute of Technology
(MIT), and Harvard. B.D. was supported by a fellowship from the NSF
(GRFP 1122374). T.K., B.D., and R. W. are listed as coinventors on
patents (granted or pending) assigned to MIT that relate to methods
in mammalian synthetic biology.
Kitada et al., Science 359, eaad1067 (2018) 9 February 2018 10 of 10